Sign inJoin waitlistJoin the waitlist

Neil Shah

| Director · University of California (San Francisco) School of Medicine

Credentials: · · · ·

History

University of California (San Francisco) School of Medicine
Present
University of California, San Francisco
Present
UCSF Health
Present

Hematology and Medical Oncology
University of California-Los Angeles
1999–2002
Internal Medicine
University of California-Los Angeles
1996–1999
UCLA
David Geffen Sch of Med at UCLA
1992–1996

Research

Overriding imatinib resistance with a novel ABL kinase inhibitor
Science · 2004 · First of 6 authors · 1,430 citations
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
New England Journal of Medicine · 2006 · 1,365 citations
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
New England Journal of Medicine · 2010 · 1,237 citations

Jorge Cortes
30 papers
Hagop Kantarjian
27 papers
Catherine Smith
22 papers
Michael Deininger
22 papers
Jerald Radich
17 papers
CS
Charles Sawyers
16 papers
MM
Michael Mauro
16 papers
MT
Moshe Talpaz
16 papers
Daniel DeAngelo
12 papers
Javier Pinilla-Ibarz
12 papers
Vivian Oehler
11 papers
Joseph Moore
10 papers

Grants

Defining and Overriding Mechanisms of in vitro and Clinical Resistance to the First Highly Active Allosteric Kinase Inhibitor
National Cancer Institute · R01
Contact PI · $700.3K · University of California, San Francisco
2026–2031
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors That Retain Efficacy Against Common Mechanisms of Resistance
National Cancer Institute · R01
Contact PI · $3.4M · University of California, San Francisco
2020–2025
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $362.9K · University of California, San Francisco
1999–2023
Discovery and Development of a Selective Pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
National Cancer Institute · R01
PI · $1.5M · Univ of Arkansas for Med Scis
2015–2020